Abstracts tagged "Infection"

Abstract Number: 0545 • ACR Convergence 2020
The Use of Tocilizumab and Tofacitinib in Patients with Resolved Hepatitis B Infection: A Case Series
Naomi Serling-Boyd¹, Amir Mohareb², Arthur Kim², Emily Hyle² and Zachary Wallace³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, ³Massachusetts General Hospital, Newton, MA
Background/Purpose: The use of immunosuppressive medications in patients with a history of hepatitis B virus (HBV) infection is associated with an increased risk of HBV…
Abstract Number: 1004 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Rheumatoid Arthritis Patients
Soumyasri Kambhatla¹, Estefania Gauto-Mariotti² and Augustine Manadan³, ¹John H Stroger Hospital of Cook County, Riverside, IL, ²John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 1830 • ACR Convergence 2020
Adverse Drug Reactions to Trimethoprim-sulfamethoxazole as a Prophylactic Agent Against Pneumocystis Pneumonia in Patients with Systemic Lupus Erythematosus: anti-Sm Antibody as a Possible Risk Factor
Shinji Izuka¹, Hiroyuki Yamashita², Yuko Takahashi² and Hiroshi Kaneko², ¹Devision of Rheumatic Disease, National Center for Global Health and Medicine, Toshima-Ku, Tokyo, Japan, ²Devision of Rheumatic Disease, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan
Background/Purpose: Pneumocystis pneumonia (PCP) is a life-threatening infection in immunocompromised patients, including those with connective tissue diseases (CTDs), treated with corticosteroids or immunosuppressive agents. Trimethoprim-sulfamethoxazole…
Abstract Number: 0016 • ACR Convergence 2020
Differential Characteristics in Inflammatory Rheumatologic Patients with Severe and Mild COVID-19 Infection
Paula García Escudero¹, Claudia Stoye², Orlando Pompei fernández², Marta González Fernández¹, Joaquín María Belzunegui Otano³, Juan Ramón De Dios², Belén Álvarez Rodríguez², Elena Garmendia Sánchez¹, Susana Gil², Ana Ruibal-Escribano⁴, Margarida Vasques Rocha², Francisco García Llorente⁵, César Antonio Egües⁶, Edurne Guerrero⁷ and Jaime Calvo-Alén², ¹Hospital Universitario Cruces, Barakaldo, Spain, ²Hospital Universitario Araba, Vitoria-Gasteiz, Pais Vasco, Spain, ³Rheumatology Service, Hospital Universitario Donostia. San Sebastián, Spain, San Sebastian, Spain, ⁴Hospital Alfredo Espinosa, Urduliz, Pais Vasco, Spain, ⁵Hospital Universitario de Galdakao, Galdakao, Pais Vasco, Spain, ⁶Hospital Universitario Donostia, Donostia-San Sebastián, Pais Vasco, Spain, ⁷Hospital Alto Deba, Arrasate, Pais Vasco, Spain
Background/Purpose: SARS COV 2 pandemic has been an issue which has challenged the health care systems around the world. Rheumatology has been involved in two…
Abstract Number: 0554 • ACR Convergence 2020
Increased Burden of Painful Arthritis and Rheumatism Following the Chikungunya Epidemic 2006: India Rural Population Survey 2018
Arvind Chopra¹, Ravi Ghorpade², Anuradha Venugopalan¹, Manjit Saluja¹ and Kiran Adam¹, ¹Center for Rheumatic Diseases, Pune, India, ²Center for Rheumatic Diseases, Pune
Background/Purpose: A spectrum of post Chikungunya (Chik) arthritis , often RA like, were referred to an urban rheumatology centre (Pune India)during the 2006 epidemic (Arthritis…
Abstract Number: 1010 • ACR Convergence 2020
Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
Alyssa Dominique¹, Merete Hetland², Axel Finckh³, Jacques-Eric Gottenberg⁴, Florenzo Iannone⁵, Roberto Caporali⁶, Dan Nordstrom⁷, M Victoria Hernandez⁸, Carlos Sanchez-Piedra⁹, Fernando Sanchez-Alonso⁹, Karel Pavelka¹⁰, Zlatuše Křístková¹¹ and Teresa Simon¹², ¹Bristol-Myers Squibb Company, Princeton, NJ, ²The DANBIO Registry, Rigshospitalet, Glostrup, Denmark, ³Division of Rheumatology, University Hospitals of Geneva, Geneva, Switzerland, ⁴Strasbourg University Hospital, Strasbourg, France, ⁵DETO-Rheumatology Unit, University of Bari, Bari, Italy, ⁶Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Helsinki University Hospital and Helsinki University, Helsinki, Finland, ⁸Rheumatology Department, Hospital Clinic of Barcelona, Barcelona, Spain, ⁹Biobadaser, Research Unit, Sociedad Española de Reumatología, Madrid, Spain, ¹⁰Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ¹¹Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ¹²Bristol-Myers Squibb Company (at time of analysis), Princeton, NJ
Background/Purpose: Compared with the general population, patients with RA are at an increased risk of infection and certain malignancies, which may be increased further with…
Abstract Number: 1835 • ACR Convergence 2020
Evaluation of Low Dose Glucocorticoid Effects on Infection Occurrence in Systemic Lupus Erythematosus Patients
Kazuya Abe¹, Nobuyuki Yajima², Yuichi Ishikawa³, Yasuhiko Kita⁴, Ken-ei Sada⁵, Ryusuke Yoshimi⁶, Yasuhiro Shimojima⁷, Shigeru Ohno⁸, Hiroshi Kajiyama⁹, Kunihiro Ichinose¹⁰, Shuzo Sato¹¹ and Michio Fujiwara¹², ¹Department of Rheumatology, Yokohama Rosai Hospital, Chiba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan, ³Department of Rheumatology, Yokohama Rosai Hospital, Tokyo, Japan, ⁴Department of Rheumatology, Yokohama Rosai Hospital, kanagawa, ⁵Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, Okayama, Japan, ⁶Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁷Department of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan, ⁸Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ⁹Department of Rheumatology and Applied Immunology Faculty of Medicine, Saitama Medical University, Iruma-gun, Saitama, Japan, ¹⁰Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, ¹¹Fukushima Medical University School of Medicine, Department of Rheumatology, Fukushima, Japan, ¹²Department of Rheumatology, Yokohama Rosai Hospital, Kanagawa, Japan
Background/Purpose: Infection is major cause of morbidity and mortality in systemic lupus erythematosus (SLE) patient. The past exploratory study suggested various infection risk in SLE…
Abstract Number: 0057 • ACR Convergence 2020
Increased Susceptibility to Measles in Patients from Central America and Mexico in a U.S. Rheumatology Clinic
Alice Fike¹, Abhimanyu Amarnani², Yanira Ruiz-Perdomo³, Sarfaraz Hasni³, Michael Ward³ and James Katz⁴, ¹NIAMS, Bethesda, MD, ²SUNY Downstate Health Sciences University, Brooklyn, NY, ³National Institutes of Health, Bethesda, MD, ⁴NIH NIAMS, Bethesda, MD
Background/Purpose: Infections in patients with rheumatic disease are a leading cause of morbidity and mortality. Preventive measures such as immunizations can reduce the burden of…
Abstract Number: 0604 • ACR Convergence 2020
Increasing the Rate of Pneumococcal Vaccination in an Academic Rheumatology Outpatient Clinic
Maria Bacalao¹, Swathi Reddy² and Nilofar Syed³, ¹UT Southwestern, Dallas, TX, ²Veterans Affairs North Texas Healthcare System / UT Southwestern Medical Center, Dallas, TX, ³UT Southwestern Medical Center, RICHARDSON, TX
Background/Purpose: Many patients with rheumatic diseases are at increased risk of infection, including invasive pneumococcal infection, due to both disease-related abnormalities of the immune system as…
Abstract Number: 1026 • ACR Convergence 2020
The Incidence, Mortality, and Economic Burden of Potentially Preventable Infections in Systemic Lupus Erythematosus Patients
Estefania Gauto-Mariotti¹, Soumyasri Kambhatla² and Augustine Manadan³, ¹John H. Stroger Jr. Hospital of Cook County, Chicago, IL, ²John H Stroger Hospital of Cook County, Riverside, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Streptococcus pneumoniae, Herpes zoster, and influenza infections are common and potentially preventable causes of morbidity and mortality. Vaccinations have been shown to reduce infection…
Abstract Number: 1997 • ACR Convergence 2020
Immunogenicity of Adjuvanted Herpes Zoster Subunit Vaccine in Rheumatoid Arthritis Patients Treated with Janus Kinase Inhibitors and Controls: Preliminary Results
Hanna Källmark¹, Birgitta Gullstrand², Johanna Nagel³, Jon Einarsson¹, Göran Jönsson⁴, Fredrik Kahn⁵, Robin Kahn⁶, Anders Bangtsson², Tomas Bergström⁷ and Meliha Kapetanovic¹, ¹Department of Clinical Sciences Lund, Section of Rheumatology, Lund University, Lund, Sweden and Skåne University Hospital Sweden., Lund, Sweden, ²Department of Rheumatology, Clinical Sciences, Lund University Sweden, Lund, Sweden, ³Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Rheumatology, Lund, Sweden, Lund, Sweden, ⁴Lund University, Skåne University Hospital, Department of Clinical Sciences Lund, Infection Medicine, Lund, Sweden, Lund, Sweden, ⁵Division of Infection Medicine, Department of Clinical Sciences, Lund University, Lund, Sweden, Lund, Sweden, ⁶Department of Clinical Sciences Lund, Section of Pediatrics, Lund University, Lund, Sweden; Wallenberg Centre of Molecular Medicine, Lund University, Lund, Sweden, ⁷Department of Infectious Diseases, Section for Clinical Virology, Institute of Biomedicine, University of Gothenburg, Sweden, Gothenburg, Sweden
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of contracting herpes zoster (HZ) and treatment with JAnus Kinase inhibitors (JAKi) further adds on…
Abstract Number: 0069 • ACR Convergence 2020
Identification of CD13 as a Potential Cause for SARS-CoV-2-triggered Hyperinflammation and Thrombosis
Eliza Pei-Suen Tsou¹, Gautam Sule¹, Mikel Gurrea Rubio², M. Asif Amin¹, Yu Zuo¹, Jason Knight¹, Yogendra Kanthi³ and David Fox¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³Division of Cardiovascular Medicine, Ann Arbor
Background/Purpose: The ectopeptidase CD13, which is highly expressed on stromal and myeloid cells in joints, lung and other tissues, is a known receptor for many…
Abstract Number: 0622 • ACR Convergence 2020
Infection-induced MPO-ANCA Associated Vasculitis: A Systematic Review of Published Case Reports
Konstantinos Parperis¹, Loukas Kakoullis², Eleni Papachristodoulou³ and George Panos³, ¹University of Arizona College of Medicine Phoenix and University of Cyprus Medical School, Phoenix, ²University of Patras School of Health Sciences, Patras, Akhaia, Greece, ³University of Cyprus Medical School, Nicosia, Nicosia, Cyprus
Background/Purpose: Anti-myeloperoxidase (MPO) antineutrophil cytoplasmic antibody (ANCA) has been implicated in the pathogenesis of microscopic polyangiitis (MPA) and an MPO-ANCA associated glomerulonephritis; both conditions are…
Abstract Number: 1099 • ACR Convergence 2020
High Burden of Infections in Indian Patients with Idiopathic Inflammatory Myopathy: Validation of Observations from the MyoCite Dataset
Rudrarpan Chatterjee¹, Pankti Mehta², Vikas Agarwal¹ and Latika Gupta², ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, lucknow, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
Background/Purpose: Infections are a major cause of morbidity and mortality in idiopathic inflammatory myopathy (IIM), more so in India.[1-3] The objective of this study was…
Abstract Number: 0079 • ACR Convergence 2020
Analysis of COVID-19 and Rheumatology Twitter Activity During the Pandemic Months
Mosaab Mohameden¹ and Ali H.Ali², ¹University of Cincinnati College of Medicine, Cincinnati, OH, ²University of California San Francisco Fresno, Fresno, CA
Background/Purpose: Twitter is a popular social media platform that is widely used to publish information and exchange ideas. There are over 300 million active monthly…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].